Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kathleen Grant MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT00690352
First received: May 6, 2008
Last updated: May 30, 2014
Last verified: May 2014
  Purpose

This social science study hypothesizes that convicted felony drug offenders in Nebraska who participated in Specialized Substance Abuse Supervision (SSAS) as part of their probation or parole showed significantly better outcomes (specifically, less recidivism) at six months post-entrance to SSAS compared to those who did not participate in SSAS.


Condition Intervention
Substance-related Disorders
Alcohol-related Disorders
Behavioral: Specialized Substance Abuse Supervision (SSAS)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Comparing Recidivism Rates of Felony Drug Offenders in Nebraska Who Were Sentenced to, and/or Participated in, Specialized Substance Abuse Supervision (SSAS) to Those Without SSAS

Resource links provided by NLM:


Further study details as provided by University of Nebraska:

Primary Outcome Measures:
  • Recidivism [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Recidivism [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The primary outcome measure was the proportion of individuals who re-offend during the six months following sentencing. Secondary outcomes measures included the percentages who violated probation during the six months following sentencing, were incarcerated for those violations, had positive drug screens and were employed at six months.


Enrollment: 344
Study Start Date: March 2008
Study Completion Date: August 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Specialized Substance Abuse Supervision (SSAS)
    Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
    Other Names:
    • CBT
    • motivational interviewing
    • positive reinforcement
    • use of incentives
Detailed Description:

Since March 2006, Specialized Substance Abuse Supervision (SSAS) has been available at five sites in Nebraska as an enhancement of probation and parole for felony drug offenders whose scores on initial screening instruments warrant such placement. SSAS enhancements to traditional probation and parole include cognitive behavioral therapy (CBT) in groups; use of incentives; positive reinforcement; and motivational interviewing.

Records of probationers and parolees who participated in SSAS starting anytime between March 1, 2006 and February 28, 2007 were studied to assess recidivism rates. Recidivism for this study is defined as "an arrest and conviction on a new charge while on probation or parole."

The records of a matched control group of non-SSAS probationers and parolees who entered probation or parole during the same time period with similar drug felony offenses and similar screening scores were also studied. Control group was also matched, as much as possible, with similar age group, demographic data, rural/urban residence, and level of felony offense.

Investigators performed a statistical analysis to determine recidivism rates at six months post-entrance to SSAS (and for the control group, at six months post-entrance to probation or parole).

  Eligibility

Ages Eligible for Study:   17 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Probationers and parolees who participated in SSAS starting anytime between March 1, 2006 and February 28, 2007 at any of the five participating SSAS sites in Nebraska, plus matched sets of probationers and parolees who did not participated in SSAS at any of the probation/parole sites in the state of Nebraska.

Criteria

Inclusion Criteria:

  • convicted felony drug offender
  • sentenced in Nebraska
  • probationer or parolee
  • entered probation or parole or SSAS between March 1, 2006 and February 28, 2007

Exclusion Criteria:

  • convicted felony drug offender sentenced in Nebraska starting probation or parole between March 1, 2006 and February 28, 2007 who does not match SSAS probationers/parolees in terms of age, demographics, urban v. rural residence, and/or class of felony drug offense.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00690352

Locations
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68182
Sponsors and Collaborators
University of Nebraska
Investigators
Principal Investigator: Kathleen M Grant, MD University of Nebraska
  More Information

No publications provided

Responsible Party: Kathleen Grant MD, Principal Investigator, University of Nebraska
ClinicalTrials.gov Identifier: NCT00690352     History of Changes
Other Study ID Numbers: 066-08-FB
Study First Received: May 6, 2008
Last Updated: May 30, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by University of Nebraska:
Specialized Substance Abuse Supervision
SSAS
substance use disorder
felony drug offender
probation
parole
cognitive behavioral therapy
CBT

Additional relevant MeSH terms:
Alcohol-Related Disorders
Disease
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on November 20, 2014